Xstrahl enjoys strong working relationships with partners in the Medical, Life Sciences and Biology Radiation Fields.
Oncotherapy Recources Ltd
Xstrahl Ltd recently acquired Oncotherapy Resources Ltd (ORL). Through this acquisition, Xstrahl aims to strengthen its position as a leading provider of radiotherapy systems and services. Xstrahl’s experience in the UK radiotherapy market will allow ORL to provide a greater number of treatment options for UK patients suffering from cancer.
ORL aims to bring mobile, managed, radiotherapy services closer to patients. In the UK, breast cancer patients have benefited from ORL’s SD-IORT in several hospitals including Spire Montefiore Hospital in Brighton, Nuffield Health in Brighton, Spire Thames Valley and Spire Hospital in Bristol. The treatment is also already available at BMI Goring Hall in Worthing. ORL’s single dose radiotherapy treatment is expertly delivered at the point of surgery, offering patients a convenient and effective treatment experience. For more information: www.oncotherapyresources.com
Xstrahl are sole distributors of the Xoft Axxent system in the UK. The Xoft® System is FDA cleared, CE marked and licensed in a growing number of countries including the UK for the treatment of cancer. Xoft® System is a simple-to-use, portable SD-IORT device, which utilises a disposable miniature x-ray tube (50kV). Minimal radiation shielding is required, avoiding the need to adjust operating theatres and enabling medical personnel to remain with the patient during treatment. More than 2,000 breast cancer patients globally have already been treated with the Xoft® Axxent System. More information on the system can be found at www.xoftinc.com